✦ LIBER ✦
A randomized feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
✍ Scribed by S. Margolin; L. Carlsson; M. Hellstrom; P. Karlsson; E. Lidbrink; B. Linderholm; H. Lindman; P. Malmstrom; D. Skold Pettersson; J. Bergh
- Book ID
- 119598042
- Publisher
- Elsevier Science
- Year
- 2008
- Tongue
- English
- Weight
- 71 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1359-6349
No coin nor oath required. For personal study only.